Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
- Conditions
- Lymphoblastic LymphomaMixed Phenotype Acute LeukemiaAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 850
- Registration Number
- NCT06289673
- Locations
- 🇺🇸
United States, Tennessee St. Jude Children's Research Hospital, Memphis, Tennessee, United States
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
- Conditions
- Acute Myeloid Leukemia in Children
- Interventions
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Princess Maxima Center for Pediatric Oncology
- Target Recruit Count
- 60
- Registration Number
- NCT06262438
- Locations
- 🇳🇱
Princess Máxima Center for pediatric oncology, Utrecht, Netherlands
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
- Conditions
- Recurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Myelodysplastic SyndromeRecurrent Juvenile Myelomonocytic LeukemiaRefractory Childhood Acute Myeloid LeukemiaRefractory Childhood Myelodysplastic SyndromeRefractory Juvenile Myelomonocytic Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: EchocardiographyProcedure: Lumbar Puncture
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 36
- Registration Number
- NCT06247787
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸UCSF Medical Center-Mission Bay, San Francisco, California, United States
A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients
- Conditions
- Seneorineural DeafnessSudden Sensorineural Hearing Loss
- Interventions
- Biological: Placebo
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Neuracle Science Co., LTD.
- Target Recruit Count
- 118
- Registration Number
- NCT06249919
- Locations
- 🇰🇷
Yonsei University Severance Hospital, Seoul, Korea, Republic of
🇰🇷SCH University Hospital Bucheon, Bucheon, Korea, Republic of
🇰🇷Inje University Ilsan Paik Hospital, Ilsan, Korea, Republic of
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
- Conditions
- B-Cell Non-Hodgkin Lymphoma (B-NHL)
- Interventions
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 216
- Registration Number
- NCT06230224
- Locations
- 🇨🇳
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
🇪🇸Hospital Universitario Infanta Leonor, Madrid, Spain
🇪🇸Hospital Universitario Ramon y Cajal, Madrid, Spain
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
- Conditions
- AML, ChildhoodAcute Myeloid Leukemia
- Interventions
- Drug: Recombinant Human Granulocyte Colony-Stimulating Factor
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Children's Hospital of Soochow University
- Target Recruit Count
- 500
- Registration Number
- NCT06221683
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳XiangYa Hospital Central South University, Changsha, Hunan, China
🇨🇳Children's Hospital of Soochow University, Suzhou, Jiangsu, China
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
- Conditions
- T Lymphoblastic LymphomaT Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Lumbar PunctureProcedure: Multigated Acquisition ScanBiological: NavitoclaxProcedure: Positron Emission TomographyProcedure: X-Ray Imaging
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT06210750
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Conditions
- Relapsed Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaAcute Leukemia of Ambiguous Lineage
- Interventions
- Drug: intrathecal (IT) chemotherapy
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT06177067
- Locations
- 🇺🇸
Children's Mercy Hospital of Kansas City, Kansas City, Missouri, United States
🇺🇸Memorial Sloan- Kettering Cancer Center, New York, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL
- Conditions
- Philadelphia-Positive ALLLymphoblastic LeukemiaAdult ALL
- Interventions
- Procedure: allogeneic stem cell transplantationProcedure: Total body irradiation
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 150
- Registration Number
- NCT06175702
VYxeoS Liposomal Italian Observational Study iN the Real Practice
- Conditions
- Therapy-Related Acute Myeloid LeukemiaAcute Myeloid Leukemia (AML)Acute Myeloid Leukemia With Myelodysplasia-Related Changes
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT06143839
- Locations
- 🇮🇹
Azienda ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
🇮🇹Ospedale Papa Giovanni XXIII, Bergamo, Italy
🇮🇹Ospedale di Bolzano, Bolzano, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.